Issue 5 of Life Sciences Law & Business, the bimonthly published by Legalease, has just been published. Each issue typically contains seven articles: coverage includes intellectual property, regulatory and commercial issues and the writers are drawn from the ranks of practitioners on both sides of the Atlantic. This issue includes, among other items, the following:
* A review by Penny Gilbert (Bristows) of the recent House of Lords decision in Kirin-Amgen v Transkaryotic Therapies.The IPKat commends this excellent and readable publication to anyone interested in the life sciences/law interface. The articles are short, well-focused and topical and the price (�315) looks pretty fair for a specialist legal publication in this day and age.
* Paul Ranson (PharmaLaw, Stringer Saul) writing on the legal dimension to outsourcing in the pharmaceutical industries.
* A lively piece on "reach-through royalties" and patented research tools by Foley Hoag's Donald Ware (the IPKat reckons this can be a real growth area for litigation until the key points are resolved by legislation or, more likely, judicial rulings).
